Accelerated Approval: Nippon Shinyaku’s Viltepso Fails DMD Confirmatory Trial, Raising Questions

The Duchenne muscular dystrophy treatment missed its primary endpoint of time to stand from supine in the RACER53 study, raising more questions about using dystrophin changes to support accelerated approval and the ability of functional endpoints to detect clinical change.

Trail blazes
Viltepso followed the accelerated approval trail blazed by Exondys 51, but reported confirmatory trial results faster. • Source: Shutterstock

Nippon Shinyaku Co., Ltd.’s failed confirmatory trial for the Duchenne muscular dystrophy treatment Viltepso (viltolarsen) is sure to reignite questions about the use of dystrophin as a basis for accelerated approval, as well as the ability of selected functional endpoints to detect change in the disease.

On 27 May, Nippon Shinyaku announced that RACER53, a Phase III, placebo-controlled study of 77 boys with ambulatory DMD, failed...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Post-Marketing Regulation & Studies

More from Product Reviews

  • data

    New EU Filings

     
    • By 

    <p>Executive Summary</p> <p>Zanidatamab, Jazz and BeiGene’s investigational treatment for biliary tract cancer, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.</p>

  • data

    EU CHMP Opinions And MAA Updates

     
    • By 

    <p>Executive Summary</p> This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>